This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patel, R.
Right arrow Articles by Steckelberg, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patel, R.
Right arrow Articles by Steckelberg, J. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2000, p. 3438-3440, Vol. 44, No. 12
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Linezolid Therapy of Staphylococcus aureus Experimental Osteomyelitis

Robin Patel,1,2,* Kerryl E. Piper,2 Mark S. Rouse,2 and James M. Steckelberg2

Division of Clinical Microbiology1 and Division of Infectious Diseases and Infectious Diseases Research Laboratory,2 Mayo Clinic and Foundation, Rochester, Minnesota

Received 13 April 2000/Returned for modification 13 July 2000/Accepted 9 September 2000

The in vivo activity of linezolid or cefazolin against a clinical isolate of methicillin-susceptible Staphylococcus aureus (linezolid MIC, 2 µg/ml) was studied in a rat model of experimental osteomyelitis. Sixty rats with experimental S. aureus osteomyelitis were treated for 21 days with no antimicrobial, with 25 µg of linezolid per kg of body weight administered intraperitoneally twice or three times a day, or with 50 µg of cefazolin per kg administered intramuscularly three times a day. After treatment, the animals were sacrificed and the infected tibiae were processed for quantitative bacterial cultures. The results of treatment were expressed as log10 CFU/gram of bone and analyzed by rank sum analysis. The results of linezolid treatment were not significantly different from those of untreated controls, while cefazolin treatment was significantly more active than no treatment or linezolid treatment.

* Corresponding author. Mailing address: Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, MN 55905. Phone: (507) 284-3021. Fax: (507) 284-9859. E-mail: patel.robin{at}mayo.edu.

Antimicrobial Agents and Chemotherapy, December 2000, p. 3438-3440, Vol. 44, No. 12
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Del Pozo, J. L., Rouse, M. S., Euba, G., Kang, C.-I., Mandrekar, J. N., Steckelberg, J. M., Patel, R. (2009). The Electricidal Effect Is Active in an Experimental Model of Staphylococcus epidermidis Chronic Foreign Body Osteomyelitis. Antimicrob. Agents Chemother. 53: 4064-4068 [Abstract] [Full Text]  
  • Yin, L.-Y., Calhoun, J. H., Thomas, J. K., Shapiro, S., Schmitt-Hoffmann, A. (2008). Efficacies of Ceftobiprole Medocaril and Comparators in a Rabbit Model of Osteomyelitis Due to Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 52: 1618-1622 [Abstract] [Full Text]  
  • Rouse, M. S., Piper, K. E., Jacobson, M., Jacofsky, D. J., Steckelberg, J. M., Patel, R. (2006). Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J Antimicrob Chemother 57: 301-305 [Abstract] [Full Text]  
  • Razonable, R. R., Osmon, D. R., Steckelberg, J. M. (2004). Linezolid Therapy for Orthopedic Infections. Mayo Clin Proc. 79: 1137-1144 [Abstract]  
  • Darley, E. S. R., MacGowan, A. P. (2004). Antibiotic treatment of Gram-positive bone and joint infections. J Antimicrob Chemother 53: 928-935 [Abstract] [Full Text]  
  • Mogenet, I., Raetz-Dillon, S., Canonge, J.-M., Archambaud, M., Bonnet, E. (2004). Successful Treatment of Staphylococcus epidermidis Hip Prosthesis Infection with Oral Linezolid. The Annals of Pharmacotherapy 38: 986-988 [Abstract] [Full Text]  
  • Chiang, F.-Y., Climo, M. (2003). Efficacy of Linezolid Alone or in Combination with Vancomycin for Treatment of Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 3002-3004 [Abstract] [Full Text]  
  • Moellering, R. C. Jr. (2003). Linezolid: The First Oxazolidinone Antimicrobial. ANN INTERN MED 138: 135-142 [Abstract] [Full Text]  
  • Grohs, P., Kitzis, M.-D., Gutmann, L. (2003). In Vitro Bactericidal Activities of Linezolid in Combination with Vancomycin, Gentamicin, Ciprofloxacin, Fusidic Acid, and Rifampin against Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 418-420 [Abstract] [Full Text]  
  • Patel, R., Rouse, M. S., Piper, K. E., Steckelberg, J. M. (2001). Linezolid Therapy of Vancomycin-Resistant Enterococcus faecium Experimental Endocarditis. Antimicrob. Agents Chemother. 45: 621-623 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»